Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies

Value in Health

Volumn 12, Issue 2, 2009, Pages 193-201

  Barbieri, Marco ^b   Hawkins, Neil ^a   Sculpher, Mark ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Cost effectiveness analysis; Decision models; Health economics methods; Priority setting; UK NHS

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; FUNDING; HEALTH CARE SYSTEM; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; REVIEW; UNCERTAINTY; UNITED KINGDOM; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH CARE COST; HUMAN; LEGISLATION AND JURISPRUDENCE; NATIONAL HEALTH SERVICE; ORGANIZATION; PRACTICE GUIDELINE; REIMBURSEMENT; RESOURCE ALLOCATION; STATISTICAL MODEL;

PRESCRIPTION DRUG;

BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; DECISION SUPPORT TECHNIQUES; GREAT BRITAIN; GUIDELINES AS TOPIC; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MODELS, ECONOMIC; PRESCRIPTION DRUGS; RESOURCE ALLOCATION; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNCERTAINTY;

EID: 60349089058     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00441.x     Document Type: Article

References (19)

1. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value Health 2001 4 : 225 50.
2. Tarn TY, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004 10 : 5.
3. National Institute for Health and Clinical Excellence (NICE). Guide to the Single Technology Appraisal Process. London : NICE, 2006.
4. Cairns J. Providing guidance to the NHS: the Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Policy 2006 76 : 143.
5. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet 2002 360 : 711 5.
6. Sculpher M, Claxton K, Akehurst R. It's just evaluation for decision making: recent developments in, and challenges for, cost-effectiveness research. In : Smith PC, Ginnelly L, Sculpher M, eds. Health Policy and Economics. Opportunities and Challenges. Maidenhead, UK : Open University Press, 2005.
7. Miners AH, Garau M, Fidan D, Fischer AJ. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ 2005 330 : 65.
8. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006 332 : 699 703.
9. Chauhan D, Miners AH, Fischer AJ. Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups. Int J Technol Assess Health Care 2007 23 : 96 100.
10. Sackett DL, Rosenberg WMC, Gray JAM, et al. Evidence-based medicine: what it is and what it isn't. BMJ 1996 312 : 71 2.
11. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999 18 : 342 64.
12. Griffin S, Claxton K, Palmer S, Sculpher M. Dangerous omissions: the consequences of ignoring decision uncertainty. Paper presented at HESG, Summer, York, UK, 2006.
13. Bojke L, Claxton K, Palmer S, Sculpher M. Defining and characterising structural uncertainty in decision analytic models. Centre for Health Economics (CHE) Research Report 9. York, UK : CHE, University of York, 2006.
14. Coyle D, Buxton MJ, O'Brien BJ. Stratified cost-effectiveness anaylsis: a framework for establishing efficient limited use criteria. Health Econ 2003 12 : 421 7.
15. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London : NICE, 2004.
16. Scottish Medicines Consortium (SMC). Guidance to Manufacturers. Glasgow, UK : SMC, 2006. Available from: http://www.scottishmedicines.org.uk/smc/files// Economic%20question%20and%20answer%20document%20(Master%20Nov%2004).pdf [Accessed April 2, 2008].
17. Raftery J. Review of NICE's recommendations 1999-2005. BMJ 2006 332 : 1266 8.
18. Stevenson M, Lloyd Jones M, de Nigris E, et al. The Clinical Effectiveness and Cost Effectiveness of Prevention and Treatment of Osteoporosis. Available from: http://www.nice.org.uk. London : National Institute for Clinical Excellence, 2003 [Accessed April 15, 2008].
19. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998 18 (Suppl. S68 80.